EXTON, Pa., Oct. 1 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the third annual JMP Securities Healthcare Focus Conference at 2:30 P.M. ET on Monday, October 6, 2008. The conference is being held at the Le Parker Meridien Hotel in New York.
ViroPharma also announced that Robert Doody, manager, corporate communications of ViroPharma, will present at the Maxim Group Growth Conference at 10:30 A.M. ET on Tuesday, October 7, 2008. The conference is being held at the Grand Hyatt in New York.
William Roberts, vice president, corporate communications of ViroPharma, will present at the second annual Natixis Bleichroeder Hidden Gems Conference at 8:30 A.M. ET on Monday, October 13, 2008. The conference is being held at the Waldorf=Astoria in New York.
ViroPharma's presentations will be webcast live for investors through http://www.viropharma.com and available for a period of 14 days following the conferences.
About ViroPharma Incorporated
ViroPharma Incorporated is committed to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in infectious diseases including cytomegalovirus (CMV) and non-toxigenic C. difficile (NTCD).
|SOURCE ViroPharma Incorporated|
Copyright©2008 PR Newswire.
All rights reserved